{"id":15874,"date":"2021-12-14T12:49:17","date_gmt":"2021-12-14T12:49:17","guid":{"rendered":"https:\/\/incilab.az\/immunologiya-testl%c9%99r-qrupu\/"},"modified":"2023-09-14T09:02:59","modified_gmt":"2023-09-14T09:02:59","slug":"immunology-test-group","status":"publish","type":"page","link":"https:\/\/incilab.az\/en\/immunology-test-group\/","title":{"rendered":"Immunology test group"},"content":{"rendered":"

[vc_row][vc_column]

\r\n \r\n <\/div>\r\n
<\/div>
\r\n

ANT\u0130-YO<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Purkinye h\u00fcceyr\u0259si si\u00adto\u00adplazmatik anticisimi-tip 1; PCA-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Western blot<\/p>\n

Referens:\u00a0<\/strong>\u00a0N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Ad\u0259t\u0259n qad\u0131nlarda tap\u0131l\u0131r v\u0259 yumurtal\u0131q karsinomas\u0131, m\u00fclle\u00adri\u00adan neoplazma v\u0259 ya s\u00fcd v\u0259zi x\u0259r\u00ad\u00e7\u0259n\u00adgi il\u0259 \u0259laq\u0259dard\u0131r. Anti-yo pozitivliyi olan x\u0259st\u0259l\u0259rd\u0259 \u00fcmumiyy\u0259tl\u0259 yar\u0131m k\u0259skin serebellar ataksiya v\u0259 ensefa\u00adlomiyeloradikulopatiyalar olur. Skri\u00adninq test kimi istifad\u0259 olunmamal\u0131d\u0131r (H\u0259m\u00e7inin Bax Anti-Hu, Anti-Ri, Paraneoplastik panel)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-TROMBOS\u0130T ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Trombosit anticisimi; An\u00adti-trombosit\u00a0 anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0EDTA-l\u0131 v\u0259 ya sitratl\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi (EDTA-l\u0131) v\u0259 ya mavi (sitratl\u0131) qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259\u00adsi<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>5 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Flow cytometry<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>Lax\u00adtalanma, hemoliz<\/p>\n

Referens:\u00a0<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>\u0130mmun trombosito\u00adpeni\u00adya\u00adlar zaman\u0131 trombosit antisim\u00adl\u0259rinin t\u0259yinind\u0259 istifad\u0259 olunur.<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-TPO (T\u0130RO\u0130D PEROKS\u0130DAZA ANT\u0130C\u0130S\u0130ML\u018fR\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0TPO anticisiml\u0259ri; Anti-Tpo<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00add\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:<\/strong>\u00a0<60 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Autoimmun tiroid x\u0259st\u0259\u00adlikl\u0259rinin (Xa\u015fimoto tiroiditi, idio\u00adpa\u00adtik miks\u00f6dem, Graves x\u0259st\u0259liyi v\u0259 s.) t\u0259yinind\u0259 istifad\u0259 olunur. Auto\u00adim\u00admun tiroid x\u0259st\u0259liyi olan \u015f\u0259xsl\u0259rd\u0259, TPO konsentrasiyas\u0131 x\u0259st\u0259liyin \u015fid\u00add\u0259ti il\u0259 d\u00fcz m\u00fct\u0259nasibdir. H\u0259m\u00e7inin dig\u0259r b\u0259zi autoimmun x\u0259st\u0259likl\u0259r za\u00adman\u0131 da (Addison x\u0259st\u0259liyi, perni\u00adsitoz\u00a0 anemiya, I tip \u015f\u0259k\u0259rli diabet v\u0259 s.) pozitiv n\u0259tic\u0259l\u0259r \u0259ld\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-T\u0130ROQLOBUL\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Tiroqlobulin anticisiml\u0259ri<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sa\u00adr\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>\u00a0<60 U\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Qalxanab\u0259nz\u0259r v\u0259zin au\u00adto\u00adimmun x\u0259st\u0259likl\u0259rinin qiym\u0259t\u00adl\u0259ndi\u00adrilm\u0259sind\u0259 istifad\u0259 olunur. TPO anti\u00adcisiml\u0259ri il\u0259 m\u00fcqayis\u0259d\u0259 \u0259h\u0259\u00admiyy\u0259ti azd\u0131r. Hashimito ti\u00adroiditi, Graves x\u0259s\u00adt\u0259liyi, qalxa\u00adna\u00adb\u0259nz\u0259r v\u0259z karsino\u00admalar\u0131, idiopatik miksedema, per\u00adnisioz anemiya, SLE v\u0259 de-Quervain yar\u0131mk\u0259skin ti\u00adroiditind\u0259 anti-tiro\u00adqlobulin an\u00adti\u00adcism\u00adl\u0259rinin miqdar\u0131 ar\u00adt\u0131r. Normal poulyasiyan\u0131n 10%-d\u0259 az mirdarda y\u00fcks\u0259k ola bil\u0259r. H\u0259m\u00e7inin ti\u00adro\u00adqlobulin s\u0259viyy\u0259si a\u015fa\u011f\u0131 olan x\u0259s\u00adt\u0259l\u0259rd\u0259 d\u0259 anti-tiroqlobulin s\u0259\u00adviy\u00ady\u0259\u00ad\u00adsi\u00adn\u0259 bax\u0131lmal\u0131d\u0131r. Tiro\u00adqlo\u00adbulin anti\u00adci\u00adsiml\u0259rinin olmas\u0131, ti\u00adroqlo\u00adbu\u00adlinin \u00f6l\u00e7\u00fclm\u0259sind\u0259 in\u00adter\u00adferensiyaya (d\u0259yi\u00ad\u015fikliy\u0259) s\u0259b\u0259b ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANCA (ANT\u0130-NEYTROF\u0130L S\u0130TOPLAZMAT\u0130K ANT\u0130C\u0130S\u0130M)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ANCA (cANCA-pANCA)<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFR<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00admi\u00adnasiya<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Neytrofil lizosomal fer\u00adment\u00adl\u0259r\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n spesifik an\u00adticisiml\u0259ri t\u0259yin edir. Wegener gra\u00ad\u00adnu\u00adlomatozu v\u0259 sistemik vasku\u00adlitl\u0259rin (x\u00fc\u00adsusil\u0259 b\u00f6yr\u0259k v\u0259 a\u011fciy\u0259ri \u0259hat\u0259 ed\u0259n) diaqnostikas\u0131nda v\u0259 m\u00fca\u00adlic\u0259 pro\u00adsesinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olu\u00adnur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ACA (ANT\u0130-KARD\u0130OL\u0130P\u0130N ANT\u0130C\u0130S\u0130ML\u018fR\u0130 \u0130GM V\u018f \u0130GG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ACA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u201cAntifosfolipid antici\u00adsimi\u201d termini \u00fcmumiyy\u0259tl\u0259 neqativ y\u00fckl\u00fc fosfolipidl\u0259r\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259\u00adl\u0259n anticisiml\u0259r \u00fc\u00e7\u00fcn istifad\u0259 olu\u00adnur. Bu fosfolipidl\u0259rd\u0259n \u0259n \u00e7ox kar\u00addio\u00adlipin\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisml\u0259r yoxlan\u0131l\u0131r. Antikardiolipin antisi\u00adcim\u00adl\u0259ri SLE, lupusa b\u0259nz\u0259r x\u0259st\u0259likl\u0259r, b\u0259d xass\u0259li t\u00f6r\u0259m\u0259l\u0259r, infeksiyalar, d\u0259rman m\u0259n\u015f\u0259li lupus sindromlar\u0131 v\u0259 ya\u015fl\u0131larda m\u00fc\u015fahid\u0259 oluna bil\u0259r. Rev\u00ad\u00admatik x\u0259st\u0259likl\u0259rd\u0259 tap\u0131lan anti\u00adposfolipid anticisiml\u0259ri ad\u0259t\u0259n IgG tipind\u0259 v\u0259 y\u00fcks\u0259k titrd\u0259 olur. \u0130n\u00adfek\u00adsiya, d\u0259rman v\u0259 b\u0259d xass\u0259li t\u00f6r\u0259m\u0259 m\u0259n\u015f\u0259li anticisiml\u0259r is\u0259 ad\u0259t\u0259n IgM tipind\u0259 olur. H\u0259m\u00e7inin venoz v\u0259 ar\u00adte\u00adrial tromboz, trombositopeniya, se\u00adrebral-vaskulyar prosesl\u0259r v\u0259 t\u0259k\u00adrar\u00adlanan fetal d\u00fc\u015f\u00fckl\u0259rl\u0259 m\u00fc\u015fayi\u0259t olu\u00adnan antifosfolipid sindromunda da qanda antikardiolipin anticisiml\u0259ri ta\u00adp\u0131l\u0131r. Anticisim s\u0259viyy\u0259l\u0259ri zaman ke\u00e7dikc\u0259, t\u0259dric\u0259n d\u0259yi\u015fm\u0259diyind\u0259n m\u00fc\u015fahid\u0259si t\u00f6vsiy\u0259 olunmur. S\u0259rh\u0259d d\u0259y\u0259rl\u0259r\u0259 yax\u0131n n\u0259tic\u0259l\u0259r v\u0259 t\u0259k\u00adba\u00ad\u015f\u0131\u00adna IgM pozitivliyi diqq\u0259tl\u0259 qiym\u0259t\u00adl\u0259ndirilm\u0259lidir. Antifosfolipid sind\u00adromu olan x\u0259st\u0259l\u0259rin \u00e7oxunda orta v\u0259 y\u00fcks\u0259k d\u0259r\u0259c\u0259d\u0259 IgG pozitivliyi v\u0259 ya IgM v\u0259 IgG pozitivliyi birlikd\u0259 olur (Bax Antifosfatidilserin v\u0259 be\u00adta-2 qlikoprotein 1 anticisiml\u0259ri)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AChR (ASET\u0130LXOL\u0130N RESEPTOR ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AChR<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Radio receptor assay<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens: <<\/strong>0.5 nmol\/L<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Myasteniya Gravis-in di\u00adaq\u00adnozunda istifad\u0259 olunur. Myas\u00adte\u00adniya Gravis-in generaliz\u0259 olunmu\u015f v\u0259 okulyar formalar\u0131n\u0131n, x\u0259st\u0259liyin remis\u00adsiyas\u0131n\u0131n v\u0259 immunsupressiv m\u00fca\u00adlic\u0259nin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn \u0259h\u0259\u00admiy\u00ady\u0259tlidir. Bununla b\u0259rab\u0259r x\u0259st\u0259liyin \u015fidd\u0259tinin qiym\u0259tl\u0259ndirilm\u0259sind\u0259 is\u00adti\u00adfad\u0259 olun\u00admur. H\u0259m\u00e7inin timoma, amiotrofik lateral skleroz v\u0259 auto\u00adim\u00admun qaraciy\u0259r x\u0259st\u0259likl\u0259rind\u0259 d\u0259 AChR s\u0259viyy\u0259si y\u00fcks\u0259k ola bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ADACIQ H\u00dcCEYR\u018f ANT\u0130C\u0130SM\u0130 (\u0130SLET ADACIQ ANT\u0130C\u0130SM\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Pankreas islet cell anti\u00adci\u00adsimi; ICA; Adac\u0131q anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>IFR<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>I tip \u015f\u0259k\u0259rli diabet (DM) x\u0259st\u0259l\u0259rinin 90%-d\u0259 pozitivdir. I tip DM-da klinik \u0259lam\u0259tl\u0259r ba\u015flamazdan bir ne\u00e7\u0259 il \u0259vv\u0259l anticisim tap\u0131la bi\u00adl\u0259r. Diabeti olmayanlarda pozitiv \u00e7\u0131\u00adxmas\u0131 I tip DM-a meyilliyi g\u00f6st\u0259rir. Birinci d\u0259r\u0259c\u0259li yax\u0131n qohumlar\u0131nda I tip DM olan \u015f\u0259xsl\u0259rd\u0259, a\u015fa\u011f\u0131 d\u0259r\u0259\u00adc\u0259d\u0259 ICA pozitivliyi varsa, g\u0259l\u0259\u00adc\u0259kd\u0259 I tip DM inki\u015faf etm\u0259 ehtimal\u0131 40%, y\u00fcks\u0259k titrd\u0259 ICA pozitivliyi varsa 100% -dir. H\u0259m\u00e7inin \u015f\u0259k\u0259rli diabetin I v\u0259 II tipl\u0259rinin diferen\u00adsasiyas\u0131nda da istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AGA (ANT\u0130-GL\u0130AD\u0130N ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IgA v\u0259 IgG)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Gliadin anticisiml\u0259ri; AGA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontami\u00adnasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qluten adl\u0131 z\u00fclala qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259rdir. X\u00fcsusil\u0259 seliyakiya (Celiac) x\u0259st\u0259liyi v\u0259 dig\u0259r qluten\u0259 h\u0259ssas bag\u0131rsaq patolo\u00adgi\u00adyalar\u0131 (dermatitis herpetiformis v\u0259 s.) \u00fc\u00e7\u00fcn skrininq test kimi istifad\u0259 olu\u00adnur. H\u0259m\u00ad\u00e7inin diaqnozu t\u0259sdiq\u00adl\u0259nmi\u015f x\u0259s\u00adt\u0259l\u0259rd\u0259 qlutensiz p\u0259hrizin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 d\u0259 \u0259h\u0259miyy\u0259tlidir. Se\u00adli\u00adyakiya x\u0259s\u00adt\u0259liyind\u0259 IgG sin\u00adfin\u00add\u0259n olan anti\u00adcisiml\u0259rin h\u0259ssasl\u0131\u011f\u0131 da\u00adha y\u00fcks\u0259kdir. IgA qurulu\u015flu antici\u00adsim\u00adl\u0259rin s\u0259viyy\u0259si is\u0259 qlutensiz p\u0259h\u00adriz il\u0259 azal\u0131r. Gluten\u0259 m\u0259ruz qald\u0131qda is\u0259, b\u0259z\u0259n klinik\u00a0 simptomlar\u00a0 mey\u00adda\u00adna \u00e7\u0131xmazdan bir ne\u00e7\u0259 ay \u0259vv\u0259l h\u0259r iki anticisim n\u0259z\u0259r\u0259 \u00e7arpacaq d\u0259\u00adr\u0259\u00adc\u0259d\u0259 y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AGBM (ANT\u0130-QLOMERULYAR BAZAL MEMBRAN ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AGBM; Qlomerulyar bazal membran anticisimi<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 kontami\u00adnasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qlomerulonefrit, Good\u00adpasteur (Qudpas\u00e7er) sindromu v\u0259 na\u00addir hallarda is\u0259 idiopatik a\u011fciy\u0259r fib\u00adrozunun diaqnozunun m\u00fc\u0259yy\u0259n edil\u00adm\u0259si v\u0259 bu x\u0259st\u0259likl\u0259rin qiym\u0259tl\u0259n\u00addril\u00adm\u0259sind\u0259 istifad\u0259 olunur. B\u00f6yr\u0259k yumaqc\u0131\u011f\u0131n\u0131n bazal membran\u0131nda olan IV tip kollagen\u0259 qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisimdir. Eyni zamanda\u00a0 al\u00adveolyar bazal membranla \u00e7arpaz re\u00adak\u00adsiya verir v\u0259 bu x\u00fcsusiyy\u0259ti il\u0259\u00a0 Goodpasteur sinromunun diaqnosti\u00adkas\u0131nda da istifad\u0259 olunur. AGBM normal populyasiyada olmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMA (ANT\u0130-M\u0130TOXONDR\u0130AL ANT\u0130C\u0130S\u0130M)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AMA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0\u0130lkin biliar sirrozun diaq\u00adnoztikas\u0131nda istifad\u0259 olunur, amma diaqnoz t\u0259sdiql\u0259ndikd\u0259n sonra x\u0259st\u0259\u00adliyin gedi\u015fi haqq\u0131nda m\u0259lumat ver\u00admir. H\u0259m\u00e7inin CREST sindromu v\u0259 b\u0259\u00adzi autoimmun x\u0259st\u0259likl\u0259rd\u0259 d\u0259 m\u00fc\u00ad\u015fahid\u0259 oluna bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

AMA T\u0130P M-2 (ANT\u0130- M\u0130TOXONDR\u0130YAL ANT\u0130C\u0130S\u0130M T\u0130P M-2)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>AMA tip M-2<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemo\u00adliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>M-1-d\u0259n M-9-a q\u0259d\u0259r s\u0131ralanan M tipl\u0259ri i\u00e7ind\u0259 ilkin biliar sirroza \u0259n spesifik olan testdir. Ya\u0131an\u00e7\u0131 neqativlikl\u0259ri \u00e7ox nadir rast g\u0259linir. Bununla b\u0259rab\u0259r M-2 s\u0259viy\u00ady\u0259si x\u0259st\u0259liyin aktivliyi v\u0259 proqres\u00adsivliyi haqq\u0131nda m\u0259lumat verir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANA (Bax ANT\u0130-NUKLEAR ANT\u0130C\u0130S\u0130M)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ANA; FANA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFR<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 konta\u00adminasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Kollagen toxuma x\u0259st\u0259\u00adliyin\u0259 \u015f\u00fcbh\u0259 olduqda m\u00fcayin\u0259y\u0259 ba\u015f\u00adla\u00admaq \u00fc\u00e7\u00fcn ilk add\u0131md\u0131r. Sistem xa\u00adrakterli v\u0259 ya orqan spesifik auro\u00adim\u00admun x\u0259st\u0259likl\u0259rin diaqnosti\u00adka\u00ads\u0131n\u00adda is\u00adtifad\u0259 olunur. X\u00fcsusil\u0259 SLE, dis\u00ad\u00adkoid lupus erythematosus, d\u0259r\u00adman\u00adla\u00adr\u0131n s\u0259b\u0259b oldu\u011fu lupus erythe\u00adma\u00adto\u00adsus, qar\u0131\u015f\u0131q birl\u0259\u015fdirici toxuma x\u0259s\u00adt\u0259\u00ad\u00adliyi, Sj\u00f6gren sindromu, skle\u00adro\u00adder\u00admiya, CREST, revmatoid artrit, po\u00adlimiozit v\u0259 dermatomiozit kimi x\u0259s\u00adt\u0259likl\u0259rd\u0259 pozitiv olur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANNA-1 (ANT\u0130-Hu)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti neyronal nuklear an\u00adticisim-I tip; ANNA-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Western blot<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Paraneoplastik auto\u00adim\u00admun neyropatiyalar, ensefalo\u00admielo\u00adra\u00addikulopatiyalar v\u0259 ki\u00e7ik h\u00fcceyr\u0259li a\u011f\u00adciy\u0259r x\u0259r\u00e7\u0259ngi il\u0259 \u0259laq\u0259li psevdo\u00adobstruksiyalar v\u0259 h\u0259r\u0259ki poz\u011fun\u00adluq\u00adlar\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Siqaret \u00e7\u0259k\u0259nl\u0259rd\u0259 Anti-Hu po\u00adzitiv ola bil\u0259r. Skrininq test kimi stifad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANNA-2 (ANT\u0130-Ri)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti-neyronal nuklear an\u00adti\u00adcisim-tip 2; ANNA-2<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Western blot<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0S\u00fcd v\u0259zi, a\u011fciy\u0259r v\u0259 gine\u00adkoloji orqanlar\u0131n x\u0259r\u00e7\u0259ngl\u0259ri il\u0259 \u0259la\u00adq\u0259dar paraneoplastik sindromlarda tap\u0131lan v\u0259 IgG qurulu\u015funda olan se\u00adroloji markerdir. S\u0259b\u0259bi bilinm\u0259y\u0259n nevroloji x\u0259st\u0259likl\u0259r v\u0259 ya mielo\u00adpa\u00adtiyalar\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 isti\u00adfa\u00add\u0259 olunur. Skrininq test kimi isti\u00adfad\u0259 olunmamal\u0131d\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130 ds-DNT<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Double-stranded DNT anticisimi; Anti-nativ DNT; Anti-n-DNT<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0150 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>RIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0H\u0259d\u00addind\u0259n art\u0131q hemoliz v\u0259 lipemiya<\/p>\n

Referens:<\/strong>\u00a0< 5 IU\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>SLE-nin (sistimik q\u0131rm\u0131z\u0131 qurde\u015f\u0259n\u0259yi) diaqnostikas\u0131 v\u0259 m\u00fc\u015fa\u00adhi\u00add\u0259sind\u0259 istifad\u0259 olubur. Sj\u00f6gren sind\u00adromu, da\u011f\u0131n\u0131q birl\u0259\u015fdirci toxuma x\u0259st\u0259likl\u0259ri v\u0259 proqressiv sistemik skle\u00adroz zaman\u0131 da anti- ds-DNT s\u0259\u00adviy\u00ady\u0259si y\u00fcks\u0259lir<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-CCP<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>CCP; Cyclic citrullinated peptide antibody<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

Referens:<\/strong>\u00a0Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Revmatoid artritin diaq\u00adnos\u00adtikas\u0131nda istifad\u0259 olunur. Anti-CCP-nin revmatoid artritin t\u0259yinind\u0259 spesifikliyi 96%,\u00a0 h\u0259ssasl\u0131\u011f\u0131 is\u0259 78%-dir. X\u00fcsusil\u0259 erk\u0259n diqanozda \u00e7ox d\u0259\u00ady\u0259rlidir, \u00e7\u00fcnki x\u0259st\u0259l\u0259rin 70%-d\u0259 erk\u0259n m\u0259rh\u0259l\u0259d\u0259 pozitivl\u0259\u015fir. H\u0259m\u00ad\u00e7inin seroneqativ revmatoid artrit\u00adl\u0259rin 30-40%-d\u0259 d\u0259 anti-CCP\u00a0 pozi\u00adtiv t\u0259yin olunur. Anti-CCP pozitiv\u00adliyinin eroziv x\u0259st\u0259liyin g\u00f6st\u0259ricisi oldu\u011fu da m\u0259lumdur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-D\u00dcZ \u018fZ\u018fL\u018f ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>ASMA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0IFR<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontami\u00adnasiya<\/p>\n

Referens:\u00a0<\/strong>Neqativ<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Xroniki aktiv hepatitin s\u0259\u00adb\u0259binin ara\u015fd\u0131r\u0131lmas\u0131nda istifad\u0259 olu\u00adnur. Y\u00fcks\u0259k titrd\u0259 pozitivlik (>1\/80) xroniki aktiv autoimmun hepatitd\u0259n, a\u015fa\u011f\u0131 titrd\u0259 pozitivlik is\u0259 (<1\/80) ilkin biliar sirroz, virus he\u00adpa\u00adtiti v\u0259 ya xroniki alkaqol hepa\u00adti\u00adtin\u00add\u0259n \u015f\u00fcbh\u0259l\u0259nm\u0259y\u0259 \u0259sas verir. H\u0259m\u00ad\u00e7inin EBV infeksiyalar\u0131, b\u0259dxass\u0259li melanoma, s\u00fcd v\u0259zi v\u0259 yumurtal\u0131q karsinomalar\u0131, \u00f6d kis\u0259si obstruk\u00adsi\u00adyalar\u0131 v\u0259 normal populyasiyada da ASMA pozitivliyin\u0259 rast g\u0259lin\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-FOSFAT\u0130D\u0130LSER\u0130N ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IgM v\u0259 IgG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>aPS<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum (soyuq \u015f\u0259\u00adraitd\u0259 saxlan\u0131lmal\u0131d\u0131r)<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>ELISA<\/p>\n

Referens:<\/strong>\u00a0N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0Arterial v\u0259 venoz trom\u00adbem\u00adboliyaya s\u0259b\u0259b olan antifo\u00adso\u00adlipid sindromunun diaqnostikas\u0131nda istifad\u0259 olunur. Bu anticisiml\u0259rin se\u00adrumda olmas\u0131 tromboz, d\u00fc\u015f\u00fck, endo\u00adkardit, iflic, infarkt v\u0259 hemolitik ane\u00admiya il\u0259 \u0259laq\u0259dard\u0131r. Bundan ba\u015fqa, kardiolipin v\u0259 fosfatidilserin antici\u00adsim\u00adl\u0259rinin h\u0259r ikisi pozitiv olan x\u0259s\u00adt\u0259l\u0259rd\u0259 klinik a\u011f\u0131rla\u015fma riski, bu testl\u0259rd\u0259n yaln\u0131z biri pozitiv olanlara nisb\u0259t\u0259n daha y\u00fcks\u0259kdir (H\u0259m\u00e7inin bax: Anti-kardiolipin v\u0259 beta 2 qli\u00adko\u00adprotein 1 anticisiml\u0259ri)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-GAD (ANT\u0130-GLUTAMAT TUR\u015eUSU DEKARBOKS\u0130LAZA ANT\u0130C\u0130S\u0130M\u0130)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Anti-GAD,\u00a0<\/strong>Glutamat tur\u00ad\u015fusu dekarboksilaza anticisimi, GAD-65; GADA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>< 1 U\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>I tip \u015f\u0259k\u0259rli diabet, auto\u00adimmun endokrin x\u0259st\u0259likl\u0259ri (tiroidit, pernisioz anemiya v\u0259 s.) v\u0259 auto\u00adim\u00admun ensefalo\u00admiopatiyalar\u0131n diaqnos\u00adti\u00adkas\u0131nda istifad\u0259 olunur. Diaqnozu yeni t\u0259yin olunmu\u015f I tip \u015f\u0259k\u0259rli dia\u00adbet x\u0259st\u0259l\u0259rinin 70-80%-d\u0259 m\u00fc\u015fahid\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-GL\u0130AD\u0130N ANT\u0130C\u0130S\u0130ML\u018fR\u0130 IgA v\u0259 IgG<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Gliadin anticisiml\u0259ri; AGA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0100 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>EIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya, sar\u0131l\u0131q v\u0259 kontami\u00adnasiya<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Qluten adl\u0131 z\u00fclala qar\u015f\u0131 \u0259m\u0259l\u0259 g\u0259l\u0259n anticisiml\u0259rdir. X\u00fcsusil\u0259 seliyakiya (Celiac) x\u0259st\u0259liyi v\u0259 dig\u0259r qluten\u0259 h\u0259ssas bag\u0131rsaq patolo\u00adgi\u00adyalar\u0131 (dermatitis herpetiformis v\u0259 s.) \u00fc\u00e7\u00fcn skrininq test kimi istifad\u0259 olu\u00adnur. H\u0259m\u00ad\u00e7inin diaqnozu t\u0259sdiq\u00adl\u0259nmi\u015f x\u0259s\u00adt\u0259l\u0259rd\u0259 qlutensiz p\u0259hrizin m\u00fc\u015fahi\u00add\u0259\u00adsind\u0259 d\u0259 \u0259h\u0259miyy\u0259tlidir. Se\u00adli\u00adyakiya x\u0259s\u00adt\u0259liyind\u0259 IgG sin\u00adfin\u00add\u0259n olan anti\u00adcisiml\u0259rin h\u0259ssasl\u0131\u011f\u0131 da\u00adha y\u00fcks\u0259kdir. IgA qurulu\u015flu antici\u00adsim\u00adl\u0259rin s\u0259viyy\u0259si is\u0259 qlutensiz p\u0259h\u00adriz il\u0259 azal\u0131r. Gluten\u0259 m\u0259ruz qald\u0131qda is\u0259, b\u0259z\u0259n klinik\u00a0 simptomlar\u00a0 mey\u00adda\u00adna \u00e7\u0131xmazdan bir ne\u00e7\u0259 ay \u0259vv\u0259l h\u0259r iki anticisim n\u0259z\u0259r\u0259 \u00e7arpacaq d\u0259\u00adr\u0259\u00adc\u0259d\u0259 y\u00fcks\u0259l\u0259 bil\u0259r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-GLUTAMAT TUR\u015eUSU DEKARBOKS\u0130LAZA ANT\u0130C\u0130S\u0130M\u0130<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Anti-GAD,\u00a0<\/strong>Glutamat tur\u00ad\u015fusu dekarboksilaza anticisimi, GAD-65; GADA<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0250 \u03bcL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>IRMA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:\u00a0<\/strong>H\u0259d\u00addind\u0259n art\u0131q hemoliz, lipemiya, sar\u0131l\u0131q<\/p>\n

Referens:\u00a0<\/strong>< 1 U\/mL<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>I tip \u015f\u0259k\u0259rli diabet, auto\u00adimmun endokrin x\u0259st\u0259likl\u0259ri (tiroidit, pernisioz anemiya v\u0259 s.) v\u0259 auto\u00adim\u00admun ensefalo\u00admiopatiyalar\u0131n diaqnos\u00adti\u00adkas\u0131nda istifad\u0259 olunur. Diaqnozu yeni t\u0259yin olunmu\u015f I tip \u015f\u0259k\u0259rli dia\u00adbet x\u0259st\u0259l\u0259rinin 70-80%-d\u0259 m\u00fc\u015fahid\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ANT\u0130-HU<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Anti neyronal nuklear an\u00adticisim-I tip; ANNA-1<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>1 mL<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>Western blot<\/p>\n

Referens:\u00a0<\/strong>N\u0259tic\u0259d\u0259 bildirilir<\/p>\n

\u0130stifad\u0259si:\u00a0<\/strong>Paraneoplastik auto\u00adim\u00admun neyropatiyalar, ensefalo\u00admielo\u00adra\u00addikulopatiyalar v\u0259 ki\u00e7ik h\u00fcceyr\u0259li a\u011f\u00adciy\u0259r x\u0259r\u00e7\u0259ngi il\u0259 \u0259laq\u0259li psevdo\u00adobstruksiyalar v\u0259 h\u0259r\u0259ki poz\u011fun\u00adluq\u00adlar\u0131n qiym\u0259tl\u0259ndirilm\u0259sind\u0259 istifad\u0259 olu\u00adnur. Siqaret \u00e7\u0259k\u0259nl\u0259rd\u0259 Anti-Hu po\u00adzitiv ola bil\u0259r. Skrininq test kimi stifad\u0259 olunmamal\u0131d\u0131r (H\u0259m\u00e7inin Bax Anti-Ri, Anti-Yo, para\u00adneo\u00adplas\u00adtik panel)<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FREE LIGHT CHAINS (S\u018fRB\u018fST KAPPA V\u018f LAMBDA Y\u00dcNG\u00dcL Z\u018fNC\u0130RL\u018fR)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Free kappa\/lambda y\u00fcng\u00fcl zincirl\u0259ri; Free light chains; FLC<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0N\u00fc\u00admun\u0259 soyuq \u015f\u0259raitd\u0259 saxlan\u0131lmal\u0131 v\u0259 g\u00f6nd\u0259rilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Nefelometrik<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0He\u00admoliz, lipemiya<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n
S\u0259rb\u0259st kappa y\u00fcng\u00fcl z\u0259ncir<\/td>\n0.33-1.94 mg\/dL<\/td>\n<\/tr>\n
S\u0259rb\u0259st lambda y\u00fcng\u00fcl z\u0259ncir<\/td>\n0.57-2.63 mg\/dL<\/td>\n<\/tr>\n
Kappa\/lambda nisb\u0259ti<\/td>\n0.26-1.65 mg\/dL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0Bu testl\u0259r anormal mo\u00adnoklonal yaxud poliklonal y\u00fcng\u00fcl z\u0259ncir konsentrasiyas\u0131na s\u0259b\u0259b olan x\u0259st\u0259likl\u0259rin (x\u00fcsusil\u0259 monoklonal qammapatiyalar) diaqnoz v\u0259 m\u00fc\u015fa\u00adhi\u00add\u0259sind\u0259 k\u00f6m\u0259k\u00e7i kimi istifad\u0259 olu\u00adnur. Sekresiyas\u0131z multiple mieloma (NSMM), birincili sistemli ami\u00adloidozda (AL), y\u00fcng\u00fcl z\u0259ncir depo x\u0259st\u0259liyi (LCDD) v\u0259 y\u00fcng\u00fcl z\u0259ncir multiple mieloma (LCMM) x\u0259s\u0259t\u00adl\u0259\u00adrind\u0259 apar\u0131lan retrospektiv m\u00fca\u00adyi\u00adn\u0259l\u0259r testin h\u0259ssasl\u0131\u011f\u0131n\u0131 v\u0259 immun\u00adfiksasiya elektroforezini tamamlay\u0131c\u0131 olaraq istifad\u0259 olunmas\u0131n\u0131n faydas\u0131n\u0131 bildirir. S\u0259rb\u0259sy y\u00fcng\u00fcl zincir x\u0259st\u0259likl\u0259ri \u00fc\u00e7\u00fcn diaqnoz il\u0259 yana\u015f\u0131; \u0130mmunofiksasiya v\u0259 ya z\u00fclal elektro\u00adforezind\u0259 sad\u0259c\u0259 bir bant olaraq g\u00f6\u00adr\u00fcl\u0259n amma kvantifikasiyas\u0131 olun\u00admayan bu x\u0259st\u0259likl\u0259rd\u0259, x\u0259st\u0259liyin gedi\u015finin m\u00fc\u015fahid\u0259si \u00fc\u00e7\u00fcn istifad\u0259 olunur. Total kappa v\u0259 lambda y\u00fcn\u00adg\u00fcl zincir \u00f6l\u00e7\u00fclm\u0259l\u0259ri\u00a0 il\u0259 f\u0259rqli\u00a0 h\u0259s\u00adsasiyy\u0259td\u0259 olduqlar\u0131 \u00fc\u00e7\u00fcn s\u0259rb\u0259st v\u0259 total y\u00fcng\u00fcl zincir n\u0259tic\u0259l\u0259rininin qar\u015f\u0131la\u015fd\u0131r\u0131lmas\u0131 d\u00fczg\u00fcn olmaya bil\u0259r.<\/p>\n

Serumda s\u0259rb\u0259st y\u00fcng\u00fcl zincir s\u0259\u00adviyy\u0259sinin \u00f6l\u00e7\u00fclm\u0259sinin m\u0259sl\u0259h\u0259t g\u00f6r\u00fcld\u00fcy\u00fc hallar:<\/p>\n